The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

• Status: Completed
• Trial end date: 2005-10-01

Summary

The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Calcium heparin; Heparin; Otamixaban